“Janus Kinase (JAK) Inhibitors – Competitive Landscape, Technology and Pipeline Analysis, 2016”, report provides comprehensive insights about pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the pipeline drugs that fall under Janus Kinase (JAK) Inhibitors.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/209358 .
Janus Kinases belong to the group of cytoplasmic non -receptor Tyrosine kinases (NRTKs). JAKs are associated with cytokine receptors present on the surface of cells. NRTKs are primarily involved in signal transduction originating from extracellular ligands, which often interact with transmembrane receptors. They are key component in mediating signaling process such as expression of genes which are involved in proliferation, apoptosis, migration, differentiation. Janus family of kinases comprised of JAK1, JAK2, JAK3 and tyrosine kinase 2 (TYK2). They play a major role in immune defense.
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/209358 .
This report provides information on the therapeutic development based on JAK Inhibitors mechanism of action dealing with 2 marketed drugs (Tofacitinib & Ruxolitinib) and 36 active pipeline drugs. The report also covers the information for 26+ active companies involved in the therapeutic development of the products. The report also includes the information related to discontinued and dormant drugs. There are 9 discontinued and 16 dormant products.
• The report also includes the information regarding the marketed drugs and their current clinical status for various other indications for which they may receive approval in near future.
- This report also has market analysis that covers various deals, agreements, collaborations, acquisitions between various pharma giants and mid-level companies for successful development and future growth of drugs based on this mechanism of acti on.
- This report provides information on the therapeutic development based on the Janus Kinase (JAK) Inhibitors dealing with all the marketed and pipeline drugs.
- The report provides drug profile, which includes product description, MOA, licensors & collaborators, development partner and chemical information.
- This report covers the comparative analysis of Janus Kinase (JAK) Inhibitors at various stages covering Marketed, Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.
Browse Complete Report @ http://www.orbisresearch.com/reports/index/janus-kinase-jak-inhibitors-competitive-landscape-technology-and-pipeline-analysis-2017 .
Some Points From TOC:
Janus kinase Inhibitors (JAK Inhibitors) Overview
Structure and Mechanism
Janus Kinase Inhibitors
Types of JAK Inhibitors
Cytokines associated with Janus kinases and result of their mutations
JAK Inhibitors Market Analysis
Collaborations and Deals
Companies Involved in JAK Inhibitor Development
Market Drivers and Barriers
Therapeutics under Development by Companies
Late Stage Products (Phase III)
For any enquires before buying, connect with us @ email@example.com
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas – 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +9164101019
For more information contact firstname.lastname@example.org